Abstract
The protein tyrosine phosphatase family (PTP) contains a group of dual-specificity phosphatases (DUSPs) that regulate the activivity of MAP kinases (MAPKs), which are key effectors in the control of cell growth and survival in physiological and pathological processes, including cancer. These phosphatases, named as MKP-DUSPs, include the MAPK phosphatases (MKPs) as well as a group of small-size atypical DUSPs structurally and functionally related to the MKPs. MKP-DUSPs, in most of the cases, are direct inactivators of MAPKs by dephosphorylation of both the Thr and the Tyr regulatory residues at the MAPKs catalytic loop. In some other cases, MKPDUSPs regulate the activity of MAPKs indirectly, acting through upstream MAPK pathways components. The active involvement of MKP-DUSPs in oncogenesis or resistance to cancer therapies is now well documented, making the search and validation of MKP-DUSPs inhibitors a prominent area in clinical cancer research. Here, we review the current knowledge on the role of MKP-DUSPs in human cancer, the status of the preclinical development and validation of specific MKP-DUSP inhibitors, and the potential of MKP-DUSPs as targets for anti-cancer drugs.
Keywords: Protein tyrosine phosphatases (PTPs), dual-specificity phosphatases (DUSPs), MAP kinase phosphatases (MKPs), inhibitors, anti-cancer agents, JNK1, VRK3, ERK1/2, dual specificity, LNCaP, PMA
Anti-Cancer Agents in Medicinal Chemistry
Title: Dual-Specificity MAP Kinase Phosphatases as Targets of Cancer Treatment
Volume: 11 Issue: 1
Author(s): Caroline Nunes-Xavier, Carlos Roma-Mateo, Pablo Rios, Celine Tarrega, Rocio Cejudo-Marin, Lydia Tabernero and Rafael Pulido
Affiliation:
Keywords: Protein tyrosine phosphatases (PTPs), dual-specificity phosphatases (DUSPs), MAP kinase phosphatases (MKPs), inhibitors, anti-cancer agents, JNK1, VRK3, ERK1/2, dual specificity, LNCaP, PMA
Abstract: The protein tyrosine phosphatase family (PTP) contains a group of dual-specificity phosphatases (DUSPs) that regulate the activivity of MAP kinases (MAPKs), which are key effectors in the control of cell growth and survival in physiological and pathological processes, including cancer. These phosphatases, named as MKP-DUSPs, include the MAPK phosphatases (MKPs) as well as a group of small-size atypical DUSPs structurally and functionally related to the MKPs. MKP-DUSPs, in most of the cases, are direct inactivators of MAPKs by dephosphorylation of both the Thr and the Tyr regulatory residues at the MAPKs catalytic loop. In some other cases, MKPDUSPs regulate the activity of MAPKs indirectly, acting through upstream MAPK pathways components. The active involvement of MKP-DUSPs in oncogenesis or resistance to cancer therapies is now well documented, making the search and validation of MKP-DUSPs inhibitors a prominent area in clinical cancer research. Here, we review the current knowledge on the role of MKP-DUSPs in human cancer, the status of the preclinical development and validation of specific MKP-DUSP inhibitors, and the potential of MKP-DUSPs as targets for anti-cancer drugs.
Export Options
About this article
Cite this article as:
Nunes-Xavier Caroline, Roma-Mateo Carlos, Rios Pablo, Tarrega Celine, Cejudo-Marin Rocio, Tabernero Lydia and Pulido Rafael, Dual-Specificity MAP Kinase Phosphatases as Targets of Cancer Treatment, Anti-Cancer Agents in Medicinal Chemistry 2011; 11 (1) . https://dx.doi.org/10.2174/187152011794941190
DOI https://dx.doi.org/10.2174/187152011794941190 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Role of natural compounds as anti anti-cancer agents
Cancer is considered the leading cause of worldwide mortality, accounting for nearly 10 million deaths in 2022. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy remains an important approach in treatment o f several types of cancers, even though ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Role of Retinoids, Rexinoids and Thyroid Hormone in the Expression of Cytochrome P450 Enzymes
Current Drug Metabolism From the Deepest Sea Shelf to the Uppermost Kitchen Cabinet Shelf: The Quest for Novel TNF-α Inhibitors
Current Topics in Medicinal Chemistry Roles for Serotonin in Neurodevelopment: More than just Neural Transmission
Current Neuropharmacology Pathophysiology of Arterial Hypertension: Insights from Pediatric Studies
Current Pediatric Reviews Pulmonary Vasodilators in the Management of Low Cardiac Output Syndrome After Pediatric Cardiac Surgery
Current Vascular Pharmacology Patent Foramen Ovale in Cerebral Infarction
Current Cardiology Reviews The Relationship Between Cleft Lip, Maxillary Hypoplasia, Hypoxia and Phenytoin
Current Pharmaceutical Design Properties and Clinical Development of a Novel Coating Technology: The poly[bis(trifluoroethoxy)phosphazene]
Recent Patents on Drug Delivery & Formulation Dystroglycan, A Multifunctional Adaptor Protein for Signal Transduction and A Potential Therapeutic Target
Current Signal Transduction Therapy Signaling Pathways Involved in Antidepressant-Induced Cell Proliferation and Synaptic Plasticity
Current Pharmaceutical Design Metabolic Profiling in Disease Diagnosis, Toxicology and Personalized Healthcare
Current Pharmaceutical Biotechnology Growth Differentiation Factor 5 Regulation in Bone Regeneration
Current Pharmaceutical Design The Safety of Medications for the Treatment of Bipolar Disorder During Pregnancy and the Puerperium
Current Drug Safety Anticancer Mammalian Target of Rapamycin (mTOR) Signaling Pathway Inhibitors: Current Status, Challenges and Future Prospects in Management of Epilepsy
CNS & Neurological Disorders - Drug Targets Matrix Metalloproteinases
Current Medicinal Chemistry Current Status of Renal Arterial Endovascular Interventions
Current Hypertension Reviews New Vascular Disrupting Agents in Upper Gastrointestinal Malignancies
Current Medicinal Chemistry Editorial (Thematic Issue: Pharmacologic Strategies with Afterload Reduction in Low Cardiac Output Syndrome After Pediatric Cardiac Surgery)
Current Vascular Pharmacology Diagnostic Imaging of Fetal and Neonatal Abdominal and Soft Tissue Tumors
Current Pediatric Reviews Endocannabinoid Regulation of Matrix Metalloproteinases: Implications in Ischemic Stroke
Cardiovascular & Hematological Agents in Medicinal Chemistry